Incobotulinumtoxina (Xeomin) sustainably improves upper limb spasticity: Pooled analysis of two phase III trials

Toxicon ◽  
2016 ◽  
Vol 123 ◽  
pp. S47
Author(s):  
Petr Kaňovský ◽  
Elie P. Elovic ◽  
Michael C. Munin ◽  
Angelika Hanschmann ◽  
Irena Pulte ◽  
...  
PM&R ◽  
2017 ◽  
Vol 9 ◽  
pp. S159-S160
Author(s):  
Christina Marciniak ◽  
Petr Kaňovský ◽  
Michael C. Munin ◽  
Michael Althaus ◽  
Angelika Hanschmann ◽  
...  

2019 ◽  
Vol 14 (15) ◽  
pp. 1293-1308
Author(s):  
Joseph S Solomkin ◽  
Angie Sway ◽  
Kenneth Lawrence ◽  
Melanie Olesky ◽  
Sergey Izmailyan ◽  
...  

Aim: Recently approved for use in complicated intra-abdominal infection, eravacycline is a novel fluorocycline with broad spectrum of activity against resistant Gram-negative pathogens. This manuscript is a pooled analysis of two Phase III trials. Clinical efficacy: Clinical cure rates were 86.8% for eravacycline versus 87.6% for ertapenem, and 90.8% for eravacycline versus 91.2% for meropenem in the Intent to Treat (micro-ITT) populations, and 87.0% for eravacycline versus 88.8% ertapenem, and 92.4 versus 91.6% for meropenem in the Modified Intent to Treat (MITT) populations. Safety: Eravacycline is well tolerated, with lower rates of nausea, vomiting and diarrhea than other tetracyclines. Conclusion: Eravacycline is an effective new option for use in complicated intra-abdominal infections, and in particular, for the treatment of extended-spectrum β-lactamase- and carbapenem-resistant Enterobacteriaceae-expressing organisms.


Sign in / Sign up

Export Citation Format

Share Document